Cohort for people with chronic myelomonocytic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, non-interventional cohort that collects biological samples and linked anonymized clinical data from adults with CMML. Samples are taken at diagnosis and/or as the disease progresses, with or without treatment, and always alongside routine clinical tests or within other clinical trials. The study accepts patients regardless of disease stage or current treatment, provided they meet monocytosis criteria or have a confirmed CMML diagnosis and give informed consent. Patients with active uncontrolled infections (notably hepatitis B, hepatitis C, or HIV) are excluded to protect safety and sample integrity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years and over
* Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or
* Confirmed diagnosis of chronic myelomonocytic leukemia
* Regardless of stage (chronic or transformed), and whether or not currently being treated
* Signed informed consent

Exclusion Criteria:

* Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV)
* Refusal informed consent

Where it's running

• Gustave Roussy
  Villejuif, France Recruiting
• CHU Amiens Picardie
  Amiens, France Not yet recruiting
• CHU Angers
  Angers, France Not yet recruiting
• Hôpital Privé Antony
  Antony, France Not yet recruiting
• AP-HP Hôpital Avicenne
  Bobigny, France Not yet recruiting
• Centre Hospitalier Sud Francilien
  Corbeil-Essonnes, France Not yet recruiting

Study contacts

• Study coordinator: Christophe WILLEKENS
• Email: Christophe.willekens@gustaveroussy.fr
• Phone: +33 1 42 11 23 79

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Genetics of Blood Cancers in the U.S. population

  This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.

  Recruiting Rutgers, The State University of New Jersey · Piscataway, New Jersey · NCT07714044

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Triple-drug approach for AML using eganelisib with azacitidine and venetoclax

  This early-stage trial tests whether adding eganelisib to azacitidine and venetoclax can be safe and show signs of benefit in adults with acute myeloid leukemia.

  Recruiting at 2 sites Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT07439211

• Guided spiritual care sessions for adults with acute leukemia

  This will test whether adding guided spiritual care sessions helps adults hospitalized for initial treatment of acute leukemia compared with standard inpatient spiritual care.

  Recruiting University of Chicago · Chicago, Illinois · NCT07405424

• Revumenib with Mezigdomide for relapsed or refractory acute leukemia

  This trial will test whether combining revumenib and mezigdomide is safe for people aged 12 and older with relapsed or refractory acute leukemia that has KMT2A, NUP98, or NPM1 genetic changes.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT07356154

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.